nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—Methotrexate—bone cancer	0.361	0.436	CbGbCtD
Alprostadil—ABCC5—Cisplatin—bone cancer	0.355	0.43	CbGbCtD
Alprostadil—ABCC4—Methotrexate—bone cancer	0.111	0.134	CbGbCtD
Alprostadil—ABCC4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00169	0.0675	CbGpPWpGaD
Alprostadil—Anuria—Doxorubicin—bone cancer	0.0015	0.0102	CcSEcCtD
Alprostadil—Hypochromic anaemia—Epirubicin—bone cancer	0.00146	0.00991	CcSEcCtD
Alprostadil—Supraventricular extrasystoles—Doxorubicin—bone cancer	0.00141	0.00955	CcSEcCtD
Alprostadil—SLCO2B1—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00136	0.0544	CbGpPWpGaD
Alprostadil—Tooth abscess—Epirubicin—bone cancer	0.00136	0.0092	CcSEcCtD
Alprostadil—Hypochromic anaemia—Doxorubicin—bone cancer	0.00136	0.00917	CcSEcCtD
Alprostadil—Infection—Carboplatin—bone cancer	0.00134	0.00905	CcSEcCtD
Alprostadil—Prostatic disorder—Epirubicin—bone cancer	0.00134	0.00904	CcSEcCtD
Alprostadil—Tooth abscess—Doxorubicin—bone cancer	0.00126	0.00852	CcSEcCtD
Alprostadil—Prostatic disorder—Doxorubicin—bone cancer	0.00124	0.00837	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Epirubicin—bone cancer	0.00116	0.00784	CcSEcCtD
Alprostadil—Pain—Carboplatin—bone cancer	0.00115	0.00779	CcSEcCtD
Alprostadil—Pneumothorax—Epirubicin—bone cancer	0.00114	0.00773	CcSEcCtD
Alprostadil—Hyperkalaemia—Cisplatin—bone cancer	0.00109	0.00735	CcSEcCtD
Alprostadil—Wheezing—Cisplatin—bone cancer	0.00107	0.00727	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Doxorubicin—bone cancer	0.00107	0.00725	CcSEcCtD
Alprostadil—Body temperature increased—Carboplatin—bone cancer	0.00106	0.0072	CcSEcCtD
Alprostadil—Pneumothorax—Doxorubicin—bone cancer	0.00106	0.00715	CcSEcCtD
Alprostadil—Fracture—Methotrexate—bone cancer	0.00104	0.00707	CcSEcCtD
Alprostadil—Multiple fractures—Methotrexate—bone cancer	0.00104	0.00707	CcSEcCtD
Alprostadil—Local reaction—Epirubicin—bone cancer	0.00103	0.00694	CcSEcCtD
Alprostadil—Body temperature decreased—Epirubicin—bone cancer	0.00101	0.00686	CcSEcCtD
Alprostadil—Hypothermia—Epirubicin—bone cancer	0.00101	0.00686	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—DHFR—bone cancer	0.000988	0.0395	CbGpPWpGaD
Alprostadil—ABCC4—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000987	0.0394	CbGpPWpGaD
Alprostadil—Local reaction—Doxorubicin—bone cancer	0.000949	0.00642	CcSEcCtD
Alprostadil—Body temperature decreased—Doxorubicin—bone cancer	0.000937	0.00635	CcSEcCtD
Alprostadil—Hypothermia—Doxorubicin—bone cancer	0.000937	0.00635	CcSEcCtD
Alprostadil—Pelvic pain—Epirubicin—bone cancer	0.000934	0.00632	CcSEcCtD
Alprostadil—Serum creatinine increased—Epirubicin—bone cancer	0.000923	0.00625	CcSEcCtD
Alprostadil—PTGER2—Ovarian Infertility Genes—CDK4—bone cancer	0.000916	0.0366	CbGpPWpGaD
Alprostadil—Cardiac failure congestive—Cisplatin—bone cancer	0.000885	0.00599	CcSEcCtD
Alprostadil—Nasal congestion—Cisplatin—bone cancer	0.000881	0.00596	CcSEcCtD
Alprostadil—Burning sensation—Methotrexate—bone cancer	0.000873	0.00591	CcSEcCtD
Alprostadil—Pelvic pain—Doxorubicin—bone cancer	0.000864	0.00585	CcSEcCtD
Alprostadil—Serum creatinine increased—Doxorubicin—bone cancer	0.000854	0.00578	CcSEcCtD
Alprostadil—Redness—Epirubicin—bone cancer	0.000841	0.00569	CcSEcCtD
Alprostadil—Burning sensation—Epirubicin—bone cancer	0.000817	0.00553	CcSEcCtD
Alprostadil—Fungal infection—Methotrexate—bone cancer	0.000786	0.00532	CcSEcCtD
Alprostadil—Redness—Doxorubicin—bone cancer	0.000778	0.00527	CcSEcCtD
Alprostadil—Burning sensation—Doxorubicin—bone cancer	0.000756	0.00512	CcSEcCtD
Alprostadil—Blood creatinine increased—Cisplatin—bone cancer	0.000752	0.00509	CcSEcCtD
Alprostadil—Fungal infection—Epirubicin—bone cancer	0.000735	0.00498	CcSEcCtD
Alprostadil—Hypokalaemia—Cisplatin—bone cancer	0.000731	0.00495	CcSEcCtD
Alprostadil—Feeling hot—Epirubicin—bone cancer	0.000724	0.0049	CcSEcCtD
Alprostadil—Apnoea—Methotrexate—bone cancer	0.000716	0.00485	CcSEcCtD
Alprostadil—ABCC4—Ectoderm Differentiation—BCOR—bone cancer	0.000708	0.0283	CbGpPWpGaD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—GNA11—bone cancer	0.000703	0.0281	CbGpPWpGaD
Alprostadil—Injection site pain—Epirubicin—bone cancer	0.000696	0.00471	CcSEcCtD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000689	0.0275	CbGpPWpGaD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—bone cancer	0.000686	1	CrCbGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—DHFR—bone cancer	0.000685	0.0274	CbGpPWpGaD
Alprostadil—Fungal infection—Doxorubicin—bone cancer	0.000681	0.00461	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Methotrexate—bone cancer	0.000676	0.00458	CcSEcCtD
Alprostadil—Sweating increased—Cisplatin—bone cancer	0.000676	0.00457	CcSEcCtD
Alprostadil—Feeling hot—Doxorubicin—bone cancer	0.000669	0.00453	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Methotrexate—bone cancer	0.000667	0.00452	CcSEcCtD
Alprostadil—Vasodilation—Epirubicin—bone cancer	0.000646	0.00437	CcSEcCtD
Alprostadil—Vasodilation procedure—Epirubicin—bone cancer	0.000646	0.00437	CcSEcCtD
Alprostadil—Injection site pain—Doxorubicin—bone cancer	0.000644	0.00436	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000625	0.00423	CcSEcCtD
Alprostadil—Acute coronary syndrome—Cisplatin—bone cancer	0.00061	0.00413	CcSEcCtD
Alprostadil—Renal failure—Cisplatin—bone cancer	0.000608	0.00412	CcSEcCtD
Alprostadil—Myocardial infarction—Cisplatin—bone cancer	0.000606	0.0041	CcSEcCtD
Alprostadil—Vasodilation procedure—Doxorubicin—bone cancer	0.000598	0.00405	CcSEcCtD
Alprostadil—Vasodilation—Doxorubicin—bone cancer	0.000598	0.00405	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000578	0.00391	CcSEcCtD
Alprostadil—Bradycardia—Cisplatin—bone cancer	0.000565	0.00383	CcSEcCtD
Alprostadil—Injection site reaction—Epirubicin—bone cancer	0.000565	0.00382	CcSEcCtD
Alprostadil—Hyperkalaemia—Epirubicin—bone cancer	0.000558	0.00378	CcSEcCtD
Alprostadil—Influenza like illness—Epirubicin—bone cancer	0.000552	0.00373	CcSEcCtD
Alprostadil—Ecchymosis—Methotrexate—bone cancer	0.000549	0.00371	CcSEcCtD
Alprostadil—Urethral disorder—Cisplatin—bone cancer	0.000544	0.00368	CcSEcCtD
Alprostadil—Visual impairment—Cisplatin—bone cancer	0.000535	0.00362	CcSEcCtD
Alprostadil—Sepsis—Methotrexate—bone cancer	0.000527	0.00356	CcSEcCtD
Alprostadil—Injection site reaction—Doxorubicin—bone cancer	0.000522	0.00354	CcSEcCtD
Alprostadil—Cramps of lower extremities—Epirubicin—bone cancer	0.000522	0.00353	CcSEcCtD
Alprostadil—Hyperkalaemia—Doxorubicin—bone cancer	0.000516	0.00349	CcSEcCtD
Alprostadil—Flushing—Cisplatin—bone cancer	0.000515	0.00349	CcSEcCtD
Alprostadil—Ecchymosis—Epirubicin—bone cancer	0.000513	0.00348	CcSEcCtD
Alprostadil—Influenza like illness—Doxorubicin—bone cancer	0.00051	0.00345	CcSEcCtD
Alprostadil—Diabetes mellitus—Methotrexate—bone cancer	0.000506	0.00343	CcSEcCtD
Alprostadil—Abnormal vision—Epirubicin—bone cancer	0.000495	0.00335	CcSEcCtD
Alprostadil—Sepsis—Epirubicin—bone cancer	0.000493	0.00334	CcSEcCtD
Alprostadil—Erythema—Cisplatin—bone cancer	0.000483	0.00327	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—bone cancer	0.000483	0.00327	CcSEcCtD
Alprostadil—Ecchymosis—Doxorubicin—bone cancer	0.000475	0.00322	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—bone cancer	0.000474	0.00321	CcSEcCtD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000466	0.0186	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000466	0.0186	CbGpPWpGaD
Alprostadil—Muscle spasms—Cisplatin—bone cancer	0.000465	0.00315	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—bone cancer	0.000458	0.0031	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—bone cancer	0.000456	0.00309	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—bone cancer	0.000455	0.00308	CcSEcCtD
Alprostadil—Lethargy—Methotrexate—bone cancer	0.00045	0.00304	CcSEcCtD
Alprostadil—Anaemia—Cisplatin—bone cancer	0.000447	0.00302	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—bone cancer	0.000439	0.00297	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—bone cancer	0.000422	0.00286	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—bone cancer	0.000421	0.00285	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—bone cancer	0.000421	0.00285	CcSEcCtD
Alprostadil—Convulsion—Cisplatin—bone cancer	0.000419	0.00284	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—GRM1—bone cancer	0.000416	0.0166	CbGpPWpGaD
Alprostadil—Pain in extremity—Epirubicin—bone cancer	0.000412	0.00279	CcSEcCtD
Alprostadil—Discomfort—Cisplatin—bone cancer	0.000407	0.00275	CcSEcCtD
Alprostadil—Oedema—Cisplatin—bone cancer	0.000395	0.00267	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—bone cancer	0.000392	0.00265	CcSEcCtD
Alprostadil—Infection—Cisplatin—bone cancer	0.000392	0.00265	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—bone cancer	0.000391	0.00265	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—bone cancer	0.000389	0.00263	CcSEcCtD
Alprostadil—Thrombocytopenia—Cisplatin—bone cancer	0.000386	0.00261	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—bone cancer	0.000386	0.00261	CcSEcCtD
Alprostadil—Tachycardia—Cisplatin—bone cancer	0.000385	0.00261	CcSEcCtD
Alprostadil—Skin disorder—Cisplatin—bone cancer	0.000383	0.00259	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—bone cancer	0.000381	0.00258	CcSEcCtD
Alprostadil—Hyperhidrosis—Cisplatin—bone cancer	0.000381	0.00258	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—bone cancer	0.000375	0.00254	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000372	0.0149	CbGpPWpGaD
Alprostadil—Hypotension—Cisplatin—bone cancer	0.000369	0.0025	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—bone cancer	0.000363	0.00246	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—GRM4—bone cancer	0.000358	0.0143	CbGpPWpGaD
Alprostadil—Blood creatinine increased—Doxorubicin—bone cancer	0.000357	0.00242	CcSEcCtD
Alprostadil—Influenza—Epirubicin—bone cancer	0.000356	0.00241	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Methotrexate—bone cancer	0.000354	0.0024	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—bone cancer	0.000347	0.00235	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—SPARC—bone cancer	0.000345	0.0138	CbGpPWpGaD
Alprostadil—Bronchitis—Epirubicin—bone cancer	0.000343	0.00232	CcSEcCtD
Alprostadil—Pain—Cisplatin—bone cancer	0.000337	0.00228	CcSEcCtD
Alprostadil—Renal failure—Methotrexate—bone cancer	0.000334	0.00226	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—bone cancer	0.000331	0.00224	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—bone cancer	0.00033	0.00223	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—bone cancer	0.000329	0.00223	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000328	0.0131	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000326	0.013	CbGpPWpGaD
Alprostadil—Feeling abnormal—Cisplatin—bone cancer	0.000325	0.0022	CcSEcCtD
Alprostadil—Haematuria—Methotrexate—bone cancer	0.000324	0.00219	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—bone cancer	0.000321	0.00218	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—bone cancer	0.000317	0.00215	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—bone cancer	0.000312	0.00211	CcSEcCtD
Alprostadil—Body temperature increased—Cisplatin—bone cancer	0.000312	0.00211	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—GRM1—bone cancer	0.000311	0.0124	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000309	0.0124	CbGpPWpGaD
Alprostadil—Urinary tract infection—Epirubicin—bone cancer	0.000309	0.00209	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000306	0.00207	CcSEcCtD
Alprostadil—Haemoglobin—Methotrexate—bone cancer	0.000306	0.00207	CcSEcCtD
Alprostadil—Haemorrhage—Methotrexate—bone cancer	0.000305	0.00206	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—bone cancer	0.000305	0.00206	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—bone cancer	0.000303	0.00205	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—bone cancer	0.000302	0.00205	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—bone cancer	0.000299	0.00202	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—bone cancer	0.000298	0.00202	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—bone cancer	0.000297	0.00201	CcSEcCtD
Alprostadil—Visual impairment—Methotrexate—bone cancer	0.000294	0.00199	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—bone cancer	0.00029	0.00197	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—bone cancer	0.000289	0.00196	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—bone cancer	0.000287	0.00194	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—bone cancer	0.000286	0.00194	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—bone cancer	0.000286	0.00193	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—bone cancer	0.000285	0.00193	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—bone cancer	0.000284	0.00192	CcSEcCtD
Alprostadil—Asthenia—Cisplatin—bone cancer	0.000283	0.00192	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—bone cancer	0.000283	0.00192	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000282	0.0112	CbGpPWpGaD
Alprostadil—Haematuria—Doxorubicin—bone cancer	0.00028	0.0019	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—bone cancer	0.00028	0.00189	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—bone cancer	0.000276	0.00187	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—bone cancer	0.000275	0.00186	CcSEcCtD
Alprostadil—Diarrhoea—Cisplatin—bone cancer	0.00027	0.00183	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—bone cancer	0.000269	0.00182	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—GNA11—bone cancer	0.000268	0.0107	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000267	0.0107	CbGpPWpGaD
Alprostadil—Erythema—Methotrexate—bone cancer	0.000265	0.0018	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—bone cancer	0.000265	0.0018	CcSEcCtD
Alprostadil—Flushing—Epirubicin—bone cancer	0.000265	0.00179	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—bone cancer	0.000265	0.00179	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—bone cancer	0.000264	0.00179	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—bone cancer	0.000263	0.00178	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—bone cancer	0.000262	0.00177	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—bone cancer	0.000259	0.00175	CcSEcCtD
Alprostadil—Back pain—Methotrexate—bone cancer	0.000257	0.00174	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—bone cancer	0.000254	0.00172	CcSEcCtD
Alprostadil—Rash—Cisplatin—bone cancer	0.000249	0.00168	CcSEcCtD
Alprostadil—Dermatitis—Cisplatin—bone cancer	0.000249	0.00168	CcSEcCtD
Alprostadil—Erythema—Epirubicin—bone cancer	0.000248	0.00168	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—bone cancer	0.000245	0.00166	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—bone cancer	0.000245	0.00166	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—GRM4—bone cancer	0.000242	0.00967	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—GRM4—bone cancer	0.000242	0.00967	CbGpPWpGaD
Alprostadil—Nervousness—Epirubicin—bone cancer	0.000241	0.00163	CcSEcCtD
Alprostadil—Back pain—Epirubicin—bone cancer	0.00024	0.00163	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00024	0.00958	CbGpPWpGaD
Alprostadil—Muscle spasms—Epirubicin—bone cancer	0.000239	0.00162	CcSEcCtD
Alprostadil—Nausea—Cisplatin—bone cancer	0.000234	0.00159	CcSEcCtD
Alprostadil—Cough—Methotrexate—bone cancer	0.000231	0.00157	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—bone cancer	0.00023	0.00156	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—bone cancer	0.00023	0.00155	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—bone cancer	0.000229	0.00155	CcSEcCtD
Alprostadil—Discomfort—Methotrexate—bone cancer	0.000223	0.00151	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—bone cancer	0.000223	0.00151	CcSEcCtD
Alprostadil—Syncope—Epirubicin—bone cancer	0.000223	0.00151	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—bone cancer	0.000222	0.0015	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—bone cancer	0.000221	0.00149	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—bone cancer	0.000221	0.00882	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—SMO—bone cancer	0.000219	0.00874	CbGpPWpGaD
Alprostadil—Loss of consciousness—Epirubicin—bone cancer	0.000218	0.00148	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—TGFBR2—bone cancer	0.000218	0.0087	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—GSTP1—bone cancer	0.000218	0.0087	CbGpPWpGaD
Alprostadil—Cough—Epirubicin—bone cancer	0.000217	0.00147	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—bone cancer	0.000215	0.00146	CcSEcCtD
Alprostadil—Infection—Methotrexate—bone cancer	0.000215	0.00146	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—bone cancer	0.000214	0.00145	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—bone cancer	0.000212	0.00144	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—bone cancer	0.000212	0.00143	CcSEcCtD
Alprostadil—Skin disorder—Methotrexate—bone cancer	0.00021	0.00142	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—GRM1—bone cancer	0.00021	0.00838	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—GRM1—bone cancer	0.00021	0.00838	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Methotrexate—bone cancer	0.000209	0.00142	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—bone cancer	0.000209	0.00141	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—bone cancer	0.000207	0.0014	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—bone cancer	0.000206	0.00139	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—ENO2—bone cancer	0.000205	0.00818	CbGpPWpGaD
Alprostadil—Oedema—Epirubicin—bone cancer	0.000203	0.00137	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—RGS1—bone cancer	0.000202	0.00809	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—GRM4—bone cancer	0.000202	0.00809	CbGpPWpGaD
Alprostadil—Hypotension—Methotrexate—bone cancer	0.000202	0.00137	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—bone cancer	0.000202	0.00137	CcSEcCtD
Alprostadil—Infection—Epirubicin—bone cancer	0.000201	0.00136	CcSEcCtD
Alprostadil—Cough—Doxorubicin—bone cancer	0.0002	0.00136	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—EGFR—bone cancer	0.0002	0.008	CbGpPWpGaD
Alprostadil—Shock—Epirubicin—bone cancer	0.000199	0.00135	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—bone cancer	0.000199	0.00135	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—bone cancer	0.000198	0.00134	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—bone cancer	0.000198	0.00134	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—bone cancer	0.000198	0.00134	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—bone cancer	0.000197	0.00133	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—bone cancer	0.000196	0.00133	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—bone cancer	0.000193	0.00131	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—bone cancer	0.000191	0.00129	CcSEcCtD
Alprostadil—Dyspepsia—Methotrexate—bone cancer	0.000191	0.00129	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—bone cancer	0.000189	0.00128	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—bone cancer	0.000187	0.00127	CcSEcCtD
Alprostadil—Infection—Doxorubicin—bone cancer	0.000186	0.00126	CcSEcCtD
Alprostadil—Pain—Methotrexate—bone cancer	0.000185	0.00125	CcSEcCtD
Alprostadil—Shock—Doxorubicin—bone cancer	0.000184	0.00125	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—RGS1—bone cancer	0.000184	0.00734	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—GRM4—bone cancer	0.000184	0.00734	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Doxorubicin—bone cancer	0.000184	0.00124	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—bone cancer	0.000183	0.00124	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—bone cancer	0.000182	0.00123	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—bone cancer	0.000181	0.00123	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000179	0.00716	CbGpPWpGaD
Alprostadil—Feeling abnormal—Methotrexate—bone cancer	0.000178	0.00121	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—bone cancer	0.000178	0.00121	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—GRM1—bone cancer	0.000176	0.00701	CbGpPWpGaD
Alprostadil—Hypotension—Doxorubicin—bone cancer	0.000175	0.00119	CcSEcCtD
Alprostadil—Pain—Epirubicin—bone cancer	0.000173	0.00117	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000171	0.00684	CbGpPWpGaD
Alprostadil—Abdominal pain—Methotrexate—bone cancer	0.000171	0.00116	CcSEcCtD
Alprostadil—Body temperature increased—Methotrexate—bone cancer	0.000171	0.00116	CcSEcCtD
Alprostadil—Feeling abnormal—Epirubicin—bone cancer	0.000167	0.00113	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—bone cancer	0.000165	0.00112	CcSEcCtD
Alprostadil—Pain—Doxorubicin—bone cancer	0.00016	0.00109	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—bone cancer	0.00016	0.00108	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—bone cancer	0.00016	0.00108	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—GRM1—bone cancer	0.000159	0.00637	CbGpPWpGaD
Alprostadil—Asthenia—Methotrexate—bone cancer	0.000155	0.00105	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000155	0.00618	CbGpPWpGaD
Alprostadil—Feeling abnormal—Doxorubicin—bone cancer	0.000154	0.00105	CcSEcCtD
Alprostadil—Pruritus—Methotrexate—bone cancer	0.000153	0.00104	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	0.000153	0.00611	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000153	0.00611	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—TGFBR2—bone cancer	0.000151	0.00603	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—GSTP1—bone cancer	0.000151	0.00603	CbGpPWpGaD
Alprostadil—Body temperature increased—Doxorubicin—bone cancer	0.000148	0.001	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—bone cancer	0.000148	0.001	CcSEcCtD
Alprostadil—Diarrhoea—Methotrexate—bone cancer	0.000148	0.001	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000148	0.00591	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—SMO—bone cancer	0.000148	0.00591	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—SMO—bone cancer	0.000148	0.00591	CbGpPWpGaD
Alprostadil—Asthenia—Epirubicin—bone cancer	0.000145	0.000984	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—bone cancer	0.000143	0.00097	CcSEcCtD
Alprostadil—Dizziness—Methotrexate—bone cancer	0.000143	0.000969	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00014	0.00558	CbGpPWpGaD
Alprostadil—Diarrhoea—Epirubicin—bone cancer	0.000139	0.000938	CcSEcCtD
Alprostadil—PTGER1—GPCR downstream signaling—RGS1—bone cancer	0.000137	0.00546	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GRM4—bone cancer	0.000137	0.00546	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GRM4—bone cancer	0.000137	0.00546	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—RGS1—bone cancer	0.000137	0.00546	CbGpPWpGaD
Alprostadil—Rash—Methotrexate—bone cancer	0.000137	0.000924	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—bone cancer	0.000136	0.000923	CcSEcCtD
Alprostadil—Headache—Methotrexate—bone cancer	0.000136	0.000918	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—bone cancer	0.000135	0.00091	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—bone cancer	0.000134	0.000907	CcSEcCtD
Alprostadil—ABCC5—Metabolism—NDUFA12—bone cancer	0.000134	0.00535	CbGpPWpGaD
Alprostadil—Pruritus—Doxorubicin—bone cancer	0.000133	0.000898	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—SPARC—bone cancer	0.000132	0.00528	CbGpPWpGaD
Alprostadil—Nausea—Methotrexate—bone cancer	0.000129	0.00087	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—bone cancer	0.000128	0.000868	CcSEcCtD
Alprostadil—Rash—Epirubicin—bone cancer	0.000128	0.000865	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—bone cancer	0.000128	0.000864	CcSEcCtD
Alprostadil—Headache—Epirubicin—bone cancer	0.000127	0.000859	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000127	0.00506	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GRM4—bone cancer	0.000124	0.00496	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GRM4—bone cancer	0.000124	0.00496	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RGS1—bone cancer	0.000124	0.00496	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RGS1—bone cancer	0.000124	0.00496	CbGpPWpGaD
Alprostadil—Dizziness—Doxorubicin—bone cancer	0.000124	0.000839	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—GNA11—bone cancer	0.000121	0.00483	CbGpPWpGaD
Alprostadil—Nausea—Epirubicin—bone cancer	0.00012	0.000815	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000119	0.00474	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GRM1—bone cancer	0.000119	0.00474	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GRM1—bone cancer	0.000119	0.00474	CbGpPWpGaD
Alprostadil—Rash—Doxorubicin—bone cancer	0.000118	0.0008	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—bone cancer	0.000118	0.000799	CcSEcCtD
Alprostadil—Headache—Doxorubicin—bone cancer	0.000117	0.000795	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—GNA11—bone cancer	0.000113	0.00452	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—SMO—bone cancer	0.000112	0.00449	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—bone cancer	0.000111	0.000754	CcSEcCtD
Alprostadil—ABCC5—Metabolism—NT5C3A—bone cancer	0.000111	0.00443	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IL3—bone cancer	0.00011	0.00438	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RGS1—bone cancer	0.000109	0.00434	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GRM4—bone cancer	0.000109	0.00434	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GRM1—bone cancer	0.000108	0.0043	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GRM1—bone cancer	0.000108	0.0043	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—GNA11—bone cancer	0.000103	0.0041	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—IL3—bone cancer	0.000103	0.0041	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000103	0.00409	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GRM1—bone cancer	9.42e-05	0.00376	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL3—bone cancer	9.31e-05	0.00372	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SPARC—bone cancer	7.88e-05	0.00315	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GNA11—bone cancer	7.64e-05	0.00305	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GNA11—bone cancer	7.64e-05	0.00305	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—SMO—bone cancer	7.59e-05	0.00303	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—SMO—bone cancer	7.59e-05	0.00303	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RGS1—bone cancer	7.34e-05	0.00293	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GRM4—bone cancer	7.34e-05	0.00293	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GRM4—bone cancer	7.34e-05	0.00293	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RGS1—bone cancer	7.34e-05	0.00293	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—GNA11—bone cancer	7.21e-05	0.00288	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PLAU—bone cancer	7.19e-05	0.00287	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GNA11—bone cancer	6.94e-05	0.00277	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GNA11—bone cancer	6.94e-05	0.00277	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL3—bone cancer	6.93e-05	0.00277	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL3—bone cancer	6.93e-05	0.00277	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	6.83e-05	0.00273	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SMO—bone cancer	6.63e-05	0.00265	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL3—bone cancer	6.53e-05	0.00261	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GRM1—bone cancer	6.36e-05	0.00254	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GRM1—bone cancer	6.36e-05	0.00254	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL3—bone cancer	6.29e-05	0.00251	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL3—bone cancer	6.29e-05	0.00251	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GNA11—bone cancer	6.07e-05	0.00242	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ENO2—bone cancer	5.81e-05	0.00232	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ATF1—bone cancer	5.64e-05	0.00225	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL3—bone cancer	5.5e-05	0.0022	CbGpPWpGaD
Alprostadil—ABCC5—Disease—DHFR—bone cancer	5.39e-05	0.00215	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ENO2—bone cancer	4.86e-05	0.00194	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFBR2—bone cancer	4.71e-05	0.00188	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—DHFR—bone cancer	4.51e-05	0.0018	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SMO—bone cancer	4.48e-05	0.00179	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SMO—bone cancer	4.48e-05	0.00179	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1R—bone cancer	4.43e-05	0.00177	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PLAU—bone cancer	4.29e-05	0.00171	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNA11—bone cancer	4.22e-05	0.00168	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNA11—bone cancer	4.1e-05	0.00164	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNA11—bone cancer	4.1e-05	0.00164	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFBR2—bone cancer	3.9e-05	0.00156	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP3A4—bone cancer	3.82e-05	0.00153	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ATF1—bone cancer	3.81e-05	0.00152	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ATF1—bone cancer	3.81e-05	0.00152	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL3—bone cancer	3.72e-05	0.00148	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL3—bone cancer	3.72e-05	0.00148	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTP1—bone cancer	3.27e-05	0.00131	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KIT—bone cancer	3.21e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFBR2—bone cancer	3.18e-05	0.00127	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFBR2—bone cancer	3.18e-05	0.00127	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BRAF—bone cancer	3.02e-05	0.00121	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1R—bone cancer	2.99e-05	0.00119	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1R—bone cancer	2.99e-05	0.00119	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—bone cancer	2.93e-05	0.00117	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—bone cancer	2.89e-05	0.00115	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KIT—bone cancer	2.66e-05	0.00106	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MDM2—bone cancer	2.53e-05	0.00101	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BRAF—bone cancer	2.5e-05	0.001	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—JUN—bone cancer	2.2e-05	0.000878	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KIT—bone cancer	2.17e-05	0.000866	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KIT—bone cancer	2.17e-05	0.000866	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—bone cancer	2.14e-05	0.000854	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MDM2—bone cancer	2.1e-05	0.000838	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BRAF—bone cancer	2.04e-05	0.000814	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BRAF—bone cancer	2.04e-05	0.000814	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—bone cancer	2.02e-05	0.000808	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—bone cancer	1.98e-05	0.000789	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—bone cancer	1.98e-05	0.000789	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—bone cancer	1.73e-05	0.00069	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—bone cancer	1.72e-05	0.000688	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MDM2—bone cancer	1.71e-05	0.000682	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MDM2—bone cancer	1.71e-05	0.000682	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—bone cancer	1.69e-05	0.000676	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JUN—bone cancer	1.48e-05	0.000593	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JUN—bone cancer	1.48e-05	0.000593	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—bone cancer	1.45e-05	0.00058	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—bone cancer	1.44e-05	0.000577	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—bone cancer	1.44e-05	0.000577	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—bone cancer	1.43e-05	0.000573	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—bone cancer	1.17e-05	0.000466	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—bone cancer	1.17e-05	0.000466	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—bone cancer	9.8e-06	0.000391	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—bone cancer	9.8e-06	0.000391	CbGpPWpGaD
